When is amiodarone indicated for acute supraventricular tachycardia in adults, and what is the recommended intravenous and oral dosing regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Amiodarone for SVT: When and How to Use It

Amiodarone is NOT a first-line agent for acute SVT—reserve it exclusively for hemodynamically stable patients when adenosine, vagal maneuvers, beta-blockers, and calcium channel blockers have failed or are contraindicated. 1

Clinical Positioning in the Treatment Algorithm

The 2015 ACC/AHA/HRS guidelines clearly establish a hierarchical approach to acute SVT management:

First-Line Therapies (Use These First):

  • Vagal maneuvers (Valsalva, carotid massage, ice-cold towel to face)
  • Adenosine - terminates AVNRT in ~95% of cases 1
  • IV calcium channel blockers (diltiazem or verapamil) - 64-98% conversion rate 1
  • IV beta-blockers - reasonable alternative with excellent safety profile 1

When Amiodarone Becomes Appropriate:

Intravenous amiodarone may be considered for acute treatment in hemodynamically stable patients with AVNRT when other therapies are ineffective or contraindicated. 1 This represents a Class IIb recommendation (Level of Evidence: C), meaning it's a last-resort pharmacologic option before cardioversion.

Critical Distinction: Hemodynamic Status Matters

  • Hemodynamically unstable patients: Proceed directly to synchronized cardioversion—do not waste time with amiodarone 1
  • Hemodynamically stable patients: Work through the algorithm systematically before considering amiodarone

Intravenous Dosing Regimen

When amiodarone is indicated for acute SVT, use the following FDA-approved protocol 2:

Loading Dose (First 24 Hours):

  • Initial rapid infusion: 150 mg IV bolus over 10 minutes
  • Slow infusion: 1 mg/min for 6 hours (360 mg)
  • Maintenance infusion: 0.5 mg/min for 18 hours (540 mg)
  • Total first 24 hours: Approximately 1000 mg

Supplemental Dosing:

  • For breakthrough episodes: 150 mg IV over 10 minutes (can repeat)
  • Mix in 100 mL D5W to minimize hypotension risk 2

Maintenance Beyond 24 Hours:

  • Continue at 0.5 mg/min (720 mg/24 hours) for up to 2-3 weeks if needed 2
  • Use concentrations of 1-6 mg/mL
  • Critical: Concentrations >2 mg/mL require central venous access due to phlebitis risk 2

Oral Dosing for Ongoing Management

When transitioning from IV to oral or initiating oral therapy 3:

Loading Phase:

  • 600-800 mg/day in divided doses until 10 g total administered
  • Higher doses (800-1600 mg/day) may be used in inpatient settings
  • Loading typically takes 1-2 weeks

Maintenance Phase:

  • 200 mg/day for most patients 3
  • Adjust based on clinical response and side effects

Transition from IV to Oral:

  • <1 week IV: 800-1600 mg/day oral
  • 1-3 weeks IV: 600-800 mg/day oral
  • >3 weeks IV: 400 mg/day oral 3

Evidence Base and Efficacy

Research demonstrates amiodarone's effectiveness in SVT termination:

  • Small cohort studies show successful AVNRT termination 1
  • Larger observational study (142 patients): 64% conversion rate overall, with mean time to conversion of 1.2 hours for PSVT 4
  • Average effective dose: 220-340 mg for acute termination 4

However, the evidence supporting amiodarone for acute SVT is substantially weaker than for first-line agents, which is why guidelines relegate it to last-line status.

Critical Safety Considerations

Administration Requirements:

  • Must use volumetric infusion pump (not drop counters—can underdose by 30%) 2
  • Central venous catheter preferred for concentrations >2 mg/mL 2
  • In-line filter required during administration 2
  • Use glass or polyolefin bottles (not evacuated glass containers) 2

Acute Adverse Effects:

  • Hypotension (most common with rapid infusion)
  • Bradycardia and AV block
  • Phlebitis with peripheral administration 2

Long-Term Toxicity:

While short-term IV use doesn't typically cause long-term toxicity 1, oral therapy carries significant risks:

  • Pulmonary toxicity (most serious—can be fatal)
  • Thyroid dysfunction (23% incidence in some studies) 5
  • Hepatotoxicity, ocular effects, skin changes 3

Common Pitfalls to Avoid

  1. Using amiodarone as first-line therapy: This violates guideline recommendations and exposes patients to unnecessary risks when safer, more effective options exist

  2. Confusing SVT with pre-excited atrial fibrillation: In WPW with AF, AV nodal blockers (including amiodarone's acute effects) can be dangerous—cardioversion is preferred

  3. Administering too rapidly: Concentrations >3 mg/mL or rapid infusions can cause hepatocellular necrosis and acute renal failure 2

  4. Using peripheral IV for prolonged infusions: Concentrations >2 mg/mL cause severe phlebitis—use central access 2

  5. Forgetting about drug interactions: Amiodarone has extensive interactions due to its long half-life and hepatic metabolism

The Bottom Line Algorithm

For acute SVT in hemodynamically stable adults:

  1. Vagal maneuvers → 2. Adenosine 6 mg IV (then 12 mg if needed) → 3. IV diltiazem or verapamil (if no contraindications) → 4. IV beta-blockers (alternative to calcium blockers) → 5. Consider amiodarone (150 mg IV over 10 min) → 6. Synchronized cardioversion

Amiodarone occupies the penultimate position before cardioversion—use it only when you've exhausted safer options or when specific contraindications exist to first-line agents. 1

References

3
Guideline

amiodarone: guidelines for use and monitoring.

American family physician, 2003

Related Questions

What is the appropriate oral amiodarone dosing regimen for a hemodynamically stable child with supraventricular tachycardia?
After the loading dose of amiodarone, should a maintenance regimen be administered?
Can I use amiodarone for supraventricular tachycardia (SVT)?
What is the appropriate maintenance dosing of amiodarone after completing a cumulative 10 g loading course?
What oral amiodarone loading regimen should be used?
In an adult with acute portal vein thrombosis who has no severe liver disease (Child‑Pugh C), active bleeding, or pregnancy, what is the recommended rivaroxaban dosing regimen and monitoring plan?
In an elderly patient who fell without injury and whose serum sodium has decreased from 132 mEq/L to 127 mEq/L over three days, with a longstanding diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH) and who is on fluid restriction and 1 g oral sodium chloride daily, what is the appropriate management plan?
Can a patient with eosinophilic esophagitis be started on a GLP‑1 receptor agonist for glucose‑lowering therapy, and what precautions are recommended?
How does a hypertrophic obstructive cardiomyopathy (HOCM) heart behave under various loading conditions and physiological states?
What type of dressings should be used for an adult with draining stasis dermatitis and venous insufficiency?
If ovarian cysts are detected on day 2 of the menstrual cycle, what is the recommended approach to proceed with ovarian stimulation for in‑vitro fertilisation (IVF)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.